Ray Stevens, chief government officer of Construction Therapeutics Inc., throughout a Bloomberg Tv interview on the JPMorgan Healthcare Convention in San Francisco, Jan. 12, 2026.
Benjamin Fanjoy | Bloomberg | Getty Pictures
A model of this text first appeared in CNBC’s Wholesome Returns e-newsletter, which brings the newest health-care information straight to your inbox. Subscribe right here to obtain future editions.
After the launch of the first-ever GLP-1 tablet for weight reduction from Novo Nordisk this month, weight problems was prime of thoughts on the annual JPMorgan Healthcare Convention, which drew 1000’s of pharma and biotech corporations, buyers, advisors and analysts.
I sat down with Ray Stevens, the CEO of weight problems market hopeful Construction Therapeutics, in regards to the biotech’s path ahead and his expectations for the way forward for the booming GLP-1 house.
It is a massive 12 months for Construction, as the corporate’s day by day oral GLP-1 is slated to enter Part 3 trials. Shares of Construction soared greater than 100% on Dec. 9 after it launched mid-stage information exhibiting that its tablet, aleniglipron, helped sufferers with weight problems lose greater than 11% of their weight at 36 weeks, when adjusted for placebo.
Listed here are some highlights from my interview with Stevens on the convention.
What is going to outline success to your firm this 12 months?
Stevens stated 2026 is all about getting ready for the Part 3 trials on aleniglipron. He stated he believes Novo Nordisk’s now-approved tablet and an upcoming rival oral drug from Eli Lilly may have sturdy launches, and that Construction’s tablet is “subsequent in line” to enter the market.
“I believe we’ll have actually good tail winds going into that with a probably best-in-class drugs,” he informed CNBC.
Stevens stated he is pleased with the info that got here out on the drug in December, touting its “actually good efficacy” and tolerability, or information on how nicely sufferers tolerated the therapy. Within the Part 2 trial, there have been no discontinuations resulting from unwanted side effects amongst sufferers who began the drug at a low dose of two.5 milligrams.
What is going to make your tablet aggressive available in the market?
Sheldon Cooper | Lightrocket | Getty Pictures
Stevens stated there are 4 causes.
First, efficacy. The Part 2 trial in December confirmed {that a} greater, 240-milligram dose helped sufferers lose as much as 15.3% of their weight at 36 weeks, when adjusted for placebo.
Stevens stated different opponents are reporting that stage of weight reduction after an extended time interval, resembling 60 to 72 weeks.
Security is one other issue, he added. For instance, Construction noticed no drug-related liver accidents throughout research on the tablet — a problem that dogged different experimental oral weight problems remedies.
Stevens stated the third motive is the comparatively low price of producing the tablet, which is a small-molecule drug.
“We’ve the power to scale at a really giant scale, and so we will provide your entire U.S. market simply,” he stated.
The fourth issue, he stated, is that Construction’s tablet is combinable.
The corporate launched information exhibiting that it will possibly pair its oral GLP-1 with its different drug focusing on the amylin intestine hormone and obtain “actually synergistic results,” Stevens stated. He added that an oral GLP-1 might be mixed with different kinds of remedies, resembling PCSK9 inhibitors, or medicine that drastically decrease “dangerous” LDL ldl cholesterol.
“Aleniglipron could be very combinable with different medicines, so we’re excited,” Stevens stated.
What function do you imagine drugs will play within the house?
Oral medicine may broaden the market, Stevens stated. He famous that 100 million individuals within the U.S. want therapy for weight problems however solely round 5 million are receiving the prevailing injections.
The “actual progress” and uptake of the drugs goes to return from major care physicians, who write nearly all of prescriptions for People, Stevens stated.
These medical doctors choose drugs for his or her flexibility, he added.
Stevens stated he has seen circumstances the place sufferers taking the injections expertise unwanted side effects and “are simply actually sad for per week and they won’t get close to that needle ever once more.” However day by day drugs could make it simpler to take the medicine.
For instance, he stated a affected person may reduce a tablet in half to mitigate unwanted side effects on a day the place they’ve an essential assembly to attend.
What’s in retailer for the way forward for the weight problems drug market?
Stevens stated he believes combos are “going to be the subsequent part of the sphere.”
“I really feel just like the winners are actually beginning to emerge for the monotherapy” remedies, he stated. However Stevens stated the affected person inhabitants will phase in response to the opposite well being circumstances an individual has on prime of weight problems, resembling fatty liver illness, power kidney illness and heart problems.
That is the place combos can are available in, serving to deal with a situation higher than one product alone.
Wanting additional into the longer term, Stevens stated he hopes that entry and affordability are now not a problem within the house. The market has made strides over the previous 12 months. Novo Nordisk and Eli Lilly are reducing money costs for his or her injections and upcoming drugs, whereas Medicare protection for weight problems medicine will begin later this 12 months.
Stevens stated he’s “okay with the associated fee dropping as a result of to me, this has all the time been about quantity and actually making an attempt to handle a really giant unmet want globally.”
He stated he additionally hopes sufferers may have extra therapy choices sooner or later, whether or not that could be a once-monthly injectable or completely different sorts of drugs.
Be at liberty to ship any suggestions, strategies, story concepts and information to Annika at a brand new e-mail: annika.constantino@versantmedia.com.
